IZERVAY (Avacincaptad Pegol Sodium) Patent Expiration, LOE Window & CMS Spending

IZERVAY (Avacincaptad Pegol Sodium) by Astellas Pharma: FDA Orange Book core substance LOE 2027-02-14 (last listed 2034-07-11), 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstellas Pharma
FDA Application & PathwayN217225 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2027-02-14
Last Listed Patent or Exclusivity Date2034-07-11
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.